Dexmedetomidine Outperforms Stellate Block Plus Ketamine on Hemodynamics in Post-TBI Storming
This single-center Egyptian randomized trial gives critical care pharmacists the first head-to-head hemodynamic and recovery comparison of a stellate ganglion block (SGB) plus ketamine regimen against dexmedetomidine for paroxysmal sympathetic hyperactivity (PSH), though the design and internal inconsistencies limit how far the data can be applied.
📅 Journal publication: 2026(online Nov 4, 2026)·Last updated: Nov 6, 2026
Dexmedetomidine versus ketamine in PSH management after traumatic brain injury.
Paroxysmal sympathetic hyperactivity (PSH) after traumatic brain injury can complicate recovery, requiring effective management strategies. Dexmedetomidine rapidly decreased mean arterial blood pressure compared to stellate ganglion block combined with subanesthetic ketamine, though both improved neurological outcomes equally. While dexmedetomidine offers faster hemodynamic control, both treatments are effective; the choice may depend on clinical settings or resource availability. Dexmedetomidine quickly reduces blood pressure in PSH, but both treatments aid neurological recovery post-TBI.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Citation:Mohamed ESAM, Kamel AAF, Mohamed AMG, et al. Stellate Ganglion Block Combined With Subanesthetic Ketamine Versus Dexmedetomidine for the Management of Paroxysmal Sympathetic Hyperactivity (PSH) After Traumatic Brain Injury: A Randomized Trial. Critical care research and practice. 2026;2026:2779975. doi:10.1155/ccrp/2779975